Menu Search
Equities

H Lundbeck A/S

  • Add to watchlist
  • Add to portfolio
  • Add an alert
LDBB:FRA

H Lundbeck A/S

Actions
  • Price (EUR)4.72
  • Today's Change-0.045 / -0.94%
  • Shares traded1.07k
  • 1 Year change+0.21%
  • Beta0.8002
Data delayed at least 15 minutes, as of Feb 13 2026 07:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

  • Revenue in DKK (TTM)24.63bn
  • Net income in DKK3.19bn
  • Incorporated1950
  • Employees5.21k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		HLUN A:CPH since
announced		Transaction
value
Avadel Pharmaceuticals PLCDeal withdrawn14 Nov 202514 Nov 2025Deal withdrawn-0.14%2.25bn
Data delayed at least 15 minutes, as of Feb 13 2026 16:10 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.